Research programme: therapeutic cancer vaccines - igeneon

Drug Profile

Research programme: therapeutic cancer vaccines - igeneon

Alternative Names: IGN 401; IGN 402; Therapeutic cancer vaccines research programme - igeneon

Latest Information Update: 05 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Nov 2009 Discontinued - Preclinical for Cancer in Austria (unspecified route)
  • 29 Mar 2005 igeneon Krebs Immuntherapie Forschungs und Entwicklungs AG has been acquired by Aphton Corporation
  • 03 Dec 2003 Data presented at the 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer (iSBTc-2003) have been added to the Cancer immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top